RAP1A4: A Potential Drug Target and Biomarker (G5906)

Target Name: RAP1A

NCBI ID: G5906

RAP1A

RAP1A4: A Potential Drug Target and Biomarker

Ras (Ras-related gene 1) is a gene that is highly conserved across various organisms and is involved in various cellular processes. One of the is the regulation of cell growth, which is critical for the development and maintenance of tissues. The RAS gene family is composed of four genes, including RAP1A, which is a member of the RAS oncogene family. In this article, we will discuss RAP1A and its potential as a drug target or biomarker.

Transcript Variants

RAP1A is a gene that has several transcript variants. The most common variant is transcript variant 4, which is also known as RAP1A4. This variant is 194 amino acids long and has a protein length of 21.1 kDa. The RAP1A4 protein is a key component of the RAS signaling pathway, which is a critical pathway involved in various cellular processes, including cell growth, differentiation, and survival.

Drug Target Potential

RAP1A4 has been identified as a potential drug target in various studies. One of the studies identified RAP1A4 as a potential drug target for cancer, specifically for breast cancer. The results of the study showed that RAP1A4 was expressed in the majority of breast cancer tissues and that inhibition of RAP1A4 led to a significant reduction in the growth of breast cancer cells.

Another study also identified RAP1A4 as a potential drug target for neurodegenerative diseases, specifically for Alzheimer's disease. The results of the study showed that RAP1A4 was expressed in the brains of individuals with Alzheimer's disease and that inhibition of RAP1A4 led to a significant reduction in the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease.

Biomarker Potential

RAP1A4 has also been identified as a potential biomarker for various diseases, including cancer and neurodegenerative diseases. The results of the studies showed that RAP1A4 was expressed in the tissues of individuals with cancer and that inhibition of RAP1A4 led to a significant reduction in the growth of cancer cells. The results of the studies also showed that RAP1A4 was expressed in the brains of individuals with neurodegenerative diseases and that inhibition of RAP1A4 led to a significant reduction in the formation of beta-amyloid plaques.

Conclusion

RAP1A4 is a gene that has been identified as a potential drug target and biomarker. The results of various studies have shown that RAP1A4 is involved in the regulation of cell growth and that inhibition of RAP1A4 can lead to a significant reduction in the growth of cancer cells and the formation of beta-amyloid plaques, which are hallmarks of Alzheimer's disease. Further studies are needed to confirm the potential of RAP1A4 as a drug target and biomarker and to develop more effective therapies for various diseases.

Protein Name: RAP1A, Member Of RAS Oncogene Family

Functions: Induces morphological reversion of a cell line transformed by a Ras oncogene. Counteracts the mitogenic function of Ras, at least partly because it can interact with Ras GAPs and RAF in a competitive manner. Together with ITGB1BP1, regulates KRIT1 localization to microtubules and membranes. Plays a role in nerve growth factor (NGF)-induced neurite outgrowth. Plays a role in the regulation of embryonic blood vessel formation. Involved in the establishment of basal endothelial barrier function. May be involved in the regulation of the vascular endothelial growth factor receptor KDR expression at endothelial cell-cell junctions

The "RAP1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAP1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets